Kennedy, Alan; Robinson, Maximillian A; Hinze, Claudia; Waters, Erin; Williams, Cayman; Halliday, Neil; Dovedi, Simon; Kennedy, Alan; Robinson, Maximillian A; Hinze, Claudia; Waters, Erin; Williams, Cayman; Halliday, Neil; Dovedi, Simon; Sansom, David M; - view fewer (2023) The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80. The EMBO Journal , Article e111556. 10.15252/embj.2022111556.

Preview

Text The CTLA 4 immune checkpoint protein regulates PD L1 PD 1 interaction.pdf - Published Version Download (2MB) | Preview

Abstract

CTLA-4 and PD-1 are key immune checkpoint receptors that are targeted in the treatment of cancer. A recently identified physical interaction between the respective ligands, CD80 and PD-L1, has been shown to block PD-L1/PD-1 binding and to prevent PD-L1 inhibitory functions. Since CTLA-4 is known to capture and degrade its ligands via transendocytosis, we investigated the interplay between CD80 transendocytosis and CD80/PD-L1 interaction. We find that transendocytosis of CD80 results in a time-dependent recovery of PD-L1 availability that correlates with CD80 removal. Moreover, CD80 transendocytosis is highly specific in that only CD80 is internalised, while its heterodimeric PD-L1 partner remains on the plasma membrane of the antigen-presenting cell (APC). CTLA-4 interactions with CD80 do not appear to be inhibited by PD-L1, but efficient removal of CD80 requires an intact CTLA-4 cytoplasmic domain, distinguishing this process from more general trogocytosis and simple CTLA-4 binding to CD80/PD-L1 complexes. These data are consistent with CTLA-4 acting as modulator of PD-L1:PD-1 interactions via control of CD80.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item